Uncategorized
Aerie initiates first phase 3 registration trial of Roclatan
Dosing is underway for the first patients enrolled in Mercury 1, the first phase 3 registration trial of Roclatan, Aerie Pharmaceuticals announced in a press release. Roclatan is a once-daily, quadruple-action eye drop being tested for its ability to lower IOP in patients with glaucoma or ocular hypertension, the release said.